The global computational biology market is estimated to be valued at US$ 6.6 billion in 2023 and is expected to exhibit a CAGR of 17.6 % during the forecast period (2023-2030).
Increasing launch of new products in computational biology is expected to drive the global computational biology market growth. For instance, on May 31, 2023, Biognosys AG, a Switzerland-based next-generation proteomics contract research services provider, launched Spectronaut 18 and major scientific and technological advances for its proprietary proteomics research software and services. Spectronaut 18 provides DIA data analysis with unprecedented throughput and efficiency. Software and services like TrueDiscovery accelerates biomarker discovery in oncology and neuroscience, TrueTarget offers high-resolution drug target identification and deconvolution while Bruker ProteoScape a software for computational 4D Proteomics was introduced for the monitoring and optimization of system performance for timsTOF platform.
Global Computational Biology Market - Drivers
Increasing research and development with the use of computational biology are expected to drive the global computational biology market growth over the forecast period. For instance, on April 13, 2021, Peptilogics, a U.S.-based biotechnology company, announced that by using computational design to discover novel peptide therapeutics, it has successfully completed Phase 1 clinical trial for its lead compound PLG0206, a potent, broad-spectrum anti-infective used in the treatment of prosthetic joint infections. Unlike existing antibiotics, PLG0206 directly addresses the biofilm and the persister pathogens that make PJI so difficult to treat and can be administered locally to the infected site, while maintaining a very low resistance profile.
Increasing clinical trial activities using computational designs
Increasing research and development with the use of computational biology are expected to drive the global computational biology market growth over the forecast period.
Market Trends
The introduction of newer techniques for modeling and simulation can boost drug discovery and drug development which can ultimately drive the market growth. On April 1, 2021, Dassault Systèmes, a France-based multinational software corporation, launched its BIOVIA ScienceCloud platform. It will help to integrate scientific data and workflows across research and development teams.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients